Biblio

Found 359 results
[ Author(Asc)] Keyword Title Type Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
O
R. F. Ozols and Vermorken, J. B., Chemotherapy of advanced ovarian cancer: current status and future directions., Semin Oncol, vol. 24, no. 1 Suppl 2, pp. S2-1-S2-9, 1997.
R. F. Ozols, Markman, M., and Thigpen, J. T., ICON3 and chemotherapy for ovarian cancer, Lancet, vol. 360, pp. 2086-7; author reply 2088, 2002.
R. F. Ozols, Bundy, B. N., Greer, B. E., Fowler, J. M., Clarke-Pearson, D. L., Burger, R. A., Mannel, R., DeGeest, K., Hartenbach, E. M., Baergen, R., and Group, G. Oncology, Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study, J Clin Oncol, vol. 21, pp. 3194-200, 2003.
A. M. Oza, Cook, A. D., Pfisterer, J., Embleton, A. C., Ledermann, J. A., Pujade-Lauraine, E., Kristensen, G. B., Carey, M. S., Beale, P., Cervantes, A., Park-Simon, T. - W., Rustin, G. J. S., Joly, F., Mirza, M. R., Plante, M., Quinn, M., Poveda, A. M., Jayson, G. C., Stark, D., Swart, A. Marie, Farrelly, L., Kaplan, R. S., Parmar, M. K. B., and Perren, T. J., Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial., Lancet Oncol, vol. 16, no. 8, p. 936, 2015.
R. Osborne, Filiaci, V. L., J, S., Mannel, R., Lage, J., A, A. - S., J, K., Provencher, D. M., Schilder, R. J., and Miller, D. S., A randomized phase III trial comparing weekly parenteral methotrexate and "pulsed" dactinomycin as primary management for low-risk gestational trophoblastic neoplasia. , Society Gynecologic Oncologists, 2008.
A. Okamoto, Glasspool, R. M., Mabuchi, S., Matsumura, N., Nomura, H., Itamochi, H., Takano, M., Takano, T., Susumu, N., Aoki, D., Konishi, I., Covens, A., Ledermann, J. A., Mezzanzanica, D., Mezzazanica, D., Steer, C., Millan, D., McNeish, I. A., Pfisterer, J., Kang, S., Gladieff, L., Bryce, J., and Oza, A. M., Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the ovary., Int J Gynecol Cancer, vol. 24, no. 9 Suppl 3, pp. S20-5, 2014.
M. Okadome, Saito, T., Tanaka, H., Nogawa, T., Furuta, R., Watanabe, K., Kita, T., Yamamoto, K., Mikami, M., Takizawa, K., and Group, J. Gynecologi, Potential impact of combined high- and low-risk human papillomavirus infection on the progression of cervical intraepithelial neoplasia 2, J Obstet Gynaecol Res, vol. 40, pp. 561-9, 2014.
M
D. H. Moore, Blessing, J. A., McQuellon, R. P., Thaler, H. T., Cella, D., Benda, J., Miller, D. S., Olt, G., King, S., Boggess, J. F., and Rocereto, T. F., Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study, J Clin Oncol, vol. 22, pp. 3113-9, 2004.
B. J. Monk, Pujade-Lauraine, E., and Burger, R. A., Integrating bevacizumab into the management of epithelial ovarian cancer: the controversy of front-line versus recurrent disease., Ann Oncol, vol. 24 Suppl 10, p. x58, 2013.
V. Möbus, Wandt, H., Frickhofen, N., Bengala, C., Champion, K., Kimmig, R., Ostermann, H., Hinke, A., Ledermann, J. A., -OVAR/AIO, A. G. O., and , Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar/AIO and EBMT, J Clin Oncol, vol. 25, pp. 4187-93, 2007.
D. G. Mitchell, Snyder, B., Coakley, F., Reinhold, C., Thomas, G., Amendola, M., Schwartz, L. H., Woodward, P., Pannu, H., and Hricak, H., Early invasive cervical cancer: tumor delineation by magnetic resonance imaging, computed tomography, and clinical examination, verified by pathologic results, in the ACRIN 6651/GOG 183 Intergroup Study, J Clin Oncol, vol. 24, pp. 5687-94, 2006.
M. Mikami, Aoki, Y., Sakamoto, M., Shimada, M., Takeshima, N., Fujiwara, H., Matsumoto, T., Kita, T., Takizawa, K., Cervical, D. Committee, and Group, V. Cancer Jap, Current surgical principle for uterine cervical cancer of stages Ia2, Ib1, and IIa1 in Japan: a survey of the Japanese Gynecologic Oncology Group, Int J Gynecol Cancer, vol. 23, pp. 1655-60; quiz 1661-2, 2013.
M. Mikami, Aoki, Y., Sakamoto, M., Shimada, M., Takeshima, N., Fujiwara, H., Matsumoto, T., Kita, T., Takizawa, K., Cervical, D. Committee, and Group, V. Cancer Jap, Surgical Principles for Managing Stage IB2, IIA2, and IIB Uterine Cervical Cancer (Bulky Tumors) in Japan: A Survey of the Japanese Gynecologic Oncology Group, Int J Gynecol Cancer, 2014.
W. P. McGuire, Hoskins, W. J., Brady, M. F., Kucera, P. R., Partridge, E. E., Look, K. Y., Clarke-Pearson, D. L., and Davidson, M., Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer, N Engl J Med, vol. 334, pp. 1-6, 1996.
J. Martyn, Stonebraker, B., Carty, K., Bryce, J., and Bacon, M., International Harmonization of Ovarian Cancer Patient’s Tumor Assessments: A Gynecologic Cancer Intergroup (GCIG) Survey.. 2014.
G. A. Martin, Redondo, A., Jurado, M., De Juan, A., Romero, I., Bover, I., Del Campo, J. M., Cervantes, A., Garcia, Y., Lopez-Guerrero, J. A., Mendiola, C., Palacios, J., Rubio, M. J., and A. Velasco, P., GEICO (Spanish Group for Investigation on Ovarian Cancer) treatment guidelines in ovarian cancer 2012, Clin Transl Oncol, vol. 15, pp. 509-25, 2013.
C. Marth, Windbichler, G. H., Hausmaninger, H., Petru, E., Estermann, K., Pelzer, A., and Mueller-Holzner, E., Interferon-gamma in combination with carboplatin and paclitaxel as a safe and effective first-line treatment option for advanced ovarian cancer: results of a phase I/II study, Int J Gynecol Cancer, vol. 16, pp. 1522-8, 2006.
M. Markman, Bundy, B. N., Alberts, D. S., Fowler, J. M., Clarke-Pearson, D. L., Carson, L. F., Wadler, S., and Sickel, J., Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecol, J Clin Oncol, vol. 19, pp. 1001-7, 2001.
M. Markman, Liu, P. Y., Wilczynski, S. P., Monk, B. J., Copeland, L., Alvarez, R. D., Jiang, C., Alberts, D. S., Group, S. Oncology, and Group, G. Oncology, Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial, J Clin Oncol, vol. 21, pp. 2460-5, 2003.
C. Mangioni, Malmström, H., Reed, N. Simon, Scarfone, G., Poveda, A. M., Tateo, S., Pecorelli, S., Vergote, I. B., Giurgea, L., Coens, C., and Teodorovic, I., First results of a randomised trial comparing radiotherapy - versus - observation post operatively in patients with uterine sarcomas., Int J Gynecol Cancer , vol. 13, no. Suppl 1, 2003.
G. Mangili, Scarfone, G., Gadducci, A., Sigismondi, C., Ferrandina, G., Scibilia, G., Vigano, R., Tateo, S., Villa, A., and Lorusso, D., Is adjuvant chemotherapy indicated in stage I pure immature ovarian teratoma (IT)? A multicentre Italian trial in ovarian cancer (MITO-9), Gynecol Oncol, vol. 119, pp. 48-52, 2010.

Pages